FDA announces Class I recall for compounding inlets due to risk of death

The U.S. Food and Drug Administration (FDA) has issued a Class I recall on behalf of Baxter Healthcare for the company’s disposable inlets, used with ExactaMix automated compounding systems. The recall follows reports of unwanted particulate matter found within the inlets, including the sterile tubing.  

In response, the FDA and Baxter are issuing instructions on how to inspect and safely use the recalled components. The disposable inlets are for compounding drugs in hospital or clinic pharmacies before they are administered intravenously to patients. To date, there have been no reported injuries as a result of the buildup of particulate matter; however, due to the risk of serious adverse health consequences—including the potential to kill a patient—the recall is ranked as “most serious.”

What is being recalled?

The following lots of Baxter disposable inlets are subject to the recall. The ExactaMix automated compounding systems themselves are perfectly safe to use, with the issue surrounding unwanted particulate matter stemming from the inlets and associated components. 

  • Product Name: Automated Compounding Device Inlets (disposable inlet), used with the ExactaMix and ExactaMix Pro
  • Product Codes: H938173, H938174, H938175 and H938176
  • UDI: 00085412475783, 00085412475790, 00085412475806 and 00085412475813
Images of the recalled products and associated code.

For more details and a full list of affected components, click here.

Next steps

There is no need to discard the recalled inlets. However, all of the inlet—including the primary packaging, tubing, connectors and spikes—must be inspected for particulates before use. If any abnormality is observed, discard them and contact Baxter for a replacement using their web portal

If the disposable inlets are inspected and do not contain any foreign material or particulate buildup, they can be used as normal. 

To help propagate these instructions, the FDA requests the recall notice be posted so pharmacists and clinical staff are made aware of the issue. The recall notice can be found here

Baxter also sent out a letter on Aug. 20 alerting known customers to the issue. 

Chad Van Alstin Health Imaging Health Exec

Chad is an award-winning writer and editor with over 15 years of experience working in media. He has a decade-long professional background in healthcare, working as a writer and in public relations.

Around the web

When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country. 

If passed, this bill would help clinician-led clinical registries explore Medicare data for research purposes. The Society of Thoracic Surgeons and American College of Cardiology both shared public support for the bipartisan legislation. 

Cardiologists and other physicians may soon need to provide much more information when ordering remote patient monitoring for Medicare patients.

Trimed Popup
Trimed Popup